Biotechnology is a field of science that involves the use of living organisms, cells, and biological systems to develop products and technologies that improve human life and health, enhance agricultural productivity, and protect the environment. It encompasses a range of techniques, including genetic engineering, molecular biology, and bioprocessing, to manipulate biological materials for practical applications.
Biotechnology is utilized in various sectors, including medicine, where it is used to create vaccines, therapies, and diagnostic tools; agriculture, where it helps in developing genetically modified crops with desirable traits; and environmental science, where it is employed for bioremediation and waste management. The field aims to harness biological processes for sustainable solutions and innovative advancements, making it a crucial area in addressing challenges in food security, healthcare, and ecological conservation.
Peter J. Weiler appointed as new CFO of Edesa Biotech, starting May 1, 2025. Weiler brings extensive experience, with previous roles at Exzell Pharma and Biosyent Inc. Weiler holds an…
A pivotal leadership change occurs at Edesa Biotech as Peter J. Weiler is appointed CFO, bringing extensive experience in business development and pharmaceutical leadership. Weiler's background includes key roles at…
Wacker Biotech and RNAV8 Bio have formed a strategic alliance to advance mRNA-based therapies. The partnership combines Wacker’s biopharma manufacturing expertise with RNAV8’s mRNA engineering capabilities. Focus is placed on…
Peter J. Weiler appointed as Chief Financial Officer of Edesa Biotech, succeeding Stephen Lemieux. Weiler's leadership experience includes roles at Exzell Pharma, Biosyent Inc., and Cipher Pharmaceuticals. His background is…
Edesa Biotech announces the appointment of Peter J. Weiler as the new Chief Financial Officer (CFO) starting May 2025, succeeding Stephen Lemieux. Peter J. Weiler brings extensive experience from roles…
The collaboration between and heralds a new era for mRNA-based therapies, promising to redefine the biopharmaceutical landscape. Wacker Biotech offers robust manufacturing capabilities with a 650-liter fermentation capacity, crucial for…
The appointment of Peter J. Weiler as CFO marks a strategic shift for Edesa Biotech, effective May 1, 2025. Weiler brings extensive experience from roles at Exzell Pharma, Biosyent Inc.,…
Edesa Biotech has appointed Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025. Weiler brings extensive experience from leadership roles at Exzell Pharma, Biosyent Inc., and…
Wacker Biotech and RNAV8 Bio's collaboration advances mRNA-based therapies, merging manufacturing and mRNA engineering expertise. Wacker Biotech brings pharmaceutical-grade pDNA and protein production capabilities with high-capacity fermentation lines. RNAV8 Bio…
Wacker Biotech and RNAV8 Bio have joined forces to revolutionize mRNA engineering, transforming treatments for genetic and common diseases. Wacker Biotech specializes in producing high-quality mRNA and formulating lipid nanoparticles…